Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials
Background In statin trials, men and women derived similar relative risk reductions in cardiovascular events per 39 mg/dL low‐density lipoprotein cholesterol (LDL‐C) reduction. We explored whether lower LDL‐C levels and greater LDL‐C percentage reductions than those achieved with statins are associa...
Saved in:
| Main Authors: | Antonio J. Vallejo‐Vaz, Henry N. Ginsberg, Michael H. Davidson, Robert H. Eckel, Christopher P. Cannon, L. Veronica Lee, Laurence Bessac, Robert Pordy, Alexia Letierce, Kausik K. Ray |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-09-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.118.009221 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES
by: Gregory P. Geba, et al.
Published: (2024-12-01) -
Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01) -
ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01) -
PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01) -
Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors
by: Je-Wen Liou, et al.
Published: (2024-09-01)